Kiwi artist battling topical steroid withdrawal fundraising for treatment to get his ‘real skin back’
An Auckland-based artist living with debilitating symptoms of topical steroid withdrawal (TSW) believes his dermatologists ...
Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?
Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.
Business Insider6d
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitis ZORYVE, a next-generation topical phosphodiesterase-4 ...